COYACoya Therapeutics, Inc.Healthcare · Biotechnologyas of 2026-09-16
Horizon

Issued 2026-09-16 at $4.46 · now $4.46 (2026-09-16, +0.0% since)

Based on its own history, a month from the 2026-09-16 close, COYA has typically landed between $3.41 and $5.98 — a range of −23.5% to +34.1% from the issuance price $4.46.

Range of outcomes in historically similar periods — not a price prediction. Ranges are scored publicly on /methodology.
  • Actual close
  • Typical path (median)
  • Middle 50% of outcomes
  • 90% range

910 overlapping 1 month windows · 2022-12-292026-08-17 · basis climatology · forecast (batch). Probability up 53.9% (90% CI 51.756.1%, ≈1,408 obs).

The cone is anchored at the 2026-09-16 issuance close ($4.46) — the price the forecast resolves against on 2026-10-15, not the latest close. The drawn path shape is illustrative (bands widen with √t); every labeled number is real — the anchor, the scored batch p90/IQR endpoints, and the typical move.

Where COYA has typically landed a month from the 2026-09-16 close of $4.46 — the range is history, not a prediction.

$3.41worst · -23.5%$5.98best · +34.1%
  • now $4.46 (+0.0%)
  • typicalThe typical outcome — half of similar past periods did better and half did worse (not an average, so a few wild periods don't skew it). $4.44 (-0.5%)
  • middle 50%The central range of outcomes — half of similar past periods landed inside it, a quarter finished above, a quarter below. $3.95$4.92
  • 90% rangeA nine-in-ten range — in about nine of every ten similar past periods the outcome stayed within these bounds. $3.41$5.98
Actual 1-month windows behind the coneiEvery overlapping 1-month window in this security's own price history was ranked by realized return; shown are the 3 worst and 3 best of 910 windows spanning 2022-12-29 to 2026-09-16. Not cherry-picked — these are the extremes of the full sample. Max drop / max rise are the deepest and highest points reached within each window. See /methodology.
StartReturnMax dropMax rise
3 worst
2024-10-28−37.4%−40.8%+0.0%
2024-10-22−37.4%−37.4%+5.8%
2024-10-23−37.3%−37.8%+5.1%
3 best
2024-01-31+68.6%−1.2%+68.6%
2024-09-23+64.1%+0.0%+64.1%
2024-09-25+63.8%+0.0%+63.8%

910 overlapping windows · 2022-12-292026-09-16 · not cherry-picked

Seasonality · by month iHow this security has tended to do in each calendar month historically — a frequency, never a prediction.

iFor each calendar month, the share of years this security closed higher than the month before, and the average month-over-month return, over ~4 years of its own price history. Cells are shaded by average return. This is historical frequency, not a prediction — no month is a signal.
Jan
25%
−11.1%
n=4
Feb
75%
+17.9%
n=4
Mar
25%
−5.4%
n=4
Apr
75%
+5.5%
n=4
May
25%
−7.1%
n=4
Jun
50%
−0.0%
n=4
Jul
50%
−3.5%
n=4
Aug
50%
−1.1%
n=4
Sep
50%
+0.1%
n=4
Oct
100%
+15.3%
n=3
Nov
67%
+2.0%
n=3
Dec
33%
+5.3%
n=3

Up-frequency and average month-over-month return · historical frequency, not a prediction

Reported insider & political trades

Every Form 4 the people closest to this company have filed with the SEC — plotted against the share price, aggregated by month, and shown with the gap between when each trade happened and when it was disclosed. A public record, not advice.

Share price & reported tradesMonthly open-market valueReporting lag — trade date to filing date2026-092026-082026-072026-062026-052026-042026-032026-022026-012025-122025-112025-102025-092025-08$7$4↑ buys↓ sales
DatePersonRoleActionShares @ priceValueOwnership Δvs S&P 1mvs S&P 6mOwned afterFiling

The vs-S&P columns are a labeled look-back on what the stock did after each filing, measured against the index over the same window. Descriptive history, not a claim about the person or a reason to trade.

26 award / exercise / gift records — not counted as purchases

Awards, option exercises, gifts and tax-withholding disposals are shown separately and never counted as open-market purchases or sales — they carry no conviction information.

DatePersonRoleActionSharesOwned afterFiling
2026-04-09Pavao Mark HdirectorAward / grant10,00010,000Form 4
2026-01-22Swaminathan ArundirectorAward / grant293,983293,983Form 4
2026-01-22SNYDER DAVID SofficerAward / grant140,041140,041Form 4
2026-01-22Grossman FredofficerAward / grant140,041140,041Form 4
2026-01-22Berman HowarddirectorAward / grant15,25715,257Form 4
2026-01-02ROSS WILBUR L JRdirectorAward / grant10,00010,000Form 4
2026-01-02Lee AnndirectorAward / grant10,00010,000Form 4
2026-01-02Villalobos AnabelladirectorAward / grant10,00010,000Form 4
2026-01-02Weinand DieterdirectorAward / grant10,00010,000Form 4
2026-01-02GOLDSTEIN DOV A MDdirectorAward / grant10,00010,000Form 4
2025-08-18GOLDSTEIN DOV A MDdirectorOption exercise17,55727,557Form 4
2025-08-18GOLDSTEIN DOV A MDdirectorOption exercise17,5570Form 4
2025-02-25Villalobos AnabelladirectorAward / grant5,0005,000Form 4
2025-02-25GOLDSTEIN DOV A MDdirectorAward / grant5,0005,000Form 4
2025-02-25Lee AnndirectorAward / grant5,0005,000Form 4
2025-02-25ROSS WILBUR L JRdirectorAward / grant5,0005,000Form 4
2025-02-25Weinand DieterdirectorAward / grant5,0005,000Form 4
2025-01-09Berman HowarddirectorAward / grant150,602150,602Form 4
2025-01-09Grossman FredofficerAward / grant140,562140,562Form 4
2025-01-09Swaminathan ArundirectorAward / grant240,964240,964Form 4
2025-01-09SNYDER DAVID SofficerAward / grant140,562140,562Form 4
2025-01-01GOLDSTEIN DOV A MDdirectorAward / grant5,0005,000Form 4
2025-01-01ROSS WILBUR L JRdirectorAward / grant5,0005,000Form 4
2025-01-01Lee AnndirectorAward / grant5,0005,000Form 4
2025-01-01Villalobos AnabelladirectorAward / grant5,0005,000Form 4
2025-01-01Weinand DieterdirectorAward / grant5,0005,000Form 4

Source: SEC Form 4 filings. Each row links to its original filing.

Across 2012–2021, stocks where a CEO, C-suite officer, or director had recently made an open-market common-stock purchase ran about +28 bp per month above the universe average (n=34,268 stock-weeks). A historical tendency, not a prediction.

Congressional disclosures

No congressional trades disclosed for this company.

Research tool, not investment advice — historical frequencies, not recommendations. A product of Marovel Technologies LLC. Full terms.